Lilly Japan To Enlarge Domestic Market Share With New Indications
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly Japan KK plans to increase sales in Japan by seeking new indications for its existing pipeline of drugs. The subsidiary of U.S.-based Eli Lilly, the company began the program by filing for Japanese approval of Gemzar (gemcitabine), a non-small cell lung cancer medicine, for treating biliary tract cancer, and its Cialis (tadalafil) erectile dysfunction drug for treating pulmonary hypertension. The firm says seven of the 13 drugs it has in development are new applications for already-approved products. All of the planning is to reach a goal of moving into the ranks of the top 15 pharmaceuticals in the country by 2025, up from its current 23rd place. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.